Home › Companies › Myriad Genetics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Myriad Genetics, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Myriad Genetics, Inc. in the interactive database Compare manager voting policies
These tallies are Myriad Genetics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Paul M. Bisaro | 61,842,900 | 637,156 | 23,264 | -- | 15,255,311 | Majority: yes |
| Elect Director: Rashmi Kumar | 60,399,633 | 2,071,375 | 32,312 | -- | 15,255,311 | Majority: yes |
| Elect Director: Lee N. Newcomer, M.D | 61,576,936 | 894,837 | 31,547 | -- | 15,255,311 | Majority: yes |
| Proposal 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 | 76,302,595 | 1,391,172 | 64,864 | -- | -- | Majority: yes |
| Proposal 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement | 59,356,710 | 3,098,966 | 47,644 | -- | 15,255,311 | Majority: yes |
| Proposal 4: Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan | 61,812,338 | 650,741 | 40,241 | -- | 15,255,311 | Majority: yes |
| Proposal 5: Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan | 59,389,193 | 3,066,087 | 48,040 | -- | 15,255,311 | Majority: yes |
Source: Myriad Genetics, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.
Each item below shows how the 229 asset managers that disclosed a Myriad Genetics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Myriad Genetics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Proposal 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement”): 59,356,710 for, 3,098,966 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 63% for, 3% against (66% of the company cast a for/against vote).
The 225 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 8,459,645 | 817 | 0 | 0 | For |
| Vanguard | 7,558,982 | 10 | 0 | 0 | For |
| GLENVIEW CAPITAL MANAGEMENT, LLC | 5,411,978 | 0 | 0 | 0 | For |
| DE Shaw | 4,296,492 | 0 | 0 | 0 | For |
| State Street | 4,229,544 | 3,130 | 0 | 0 | For |
| Charles Schwab | 3,605,066 | 0 | 0 | 0 | For |
| Federated Hermes | 3,379,190 | 0 | 0 | 0 | For |
| Fidelity | 3,312,266 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,322,984 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 2,220,808 | 0 | 0 | Against |
| Invesco | 1,850,128 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 1,826,477 | 0 | 0 | 0 | For |
| AQR | 1,339,801 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,309,148 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,251,852 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,119,721 | 0 | 0 | 0 | For |
| Northern Trust | 952,611 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 915,070 | 0 | 0 | 0 | For |
| Two Sigma | 850,326 | 0 | 0 | 0 | For |
| Nuveen | 820,360 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 813,014 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Dimensional | 471,095 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 448,201 | 0 | 0 | 0 | For |
| WELLS FARGO CLEARING SERVICES, LLC | 438,338 | 0 | 0 | 0 | For |
Showing the 25 largest of 225 asset managers. See all 225 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Proposal 4: Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan”): 61,812,338 for, 650,741 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 65% for, 0.7% against (66% of the company cast a for/against vote).
The 66 asset managers below cast 99.9% of the shares they voted on this item FOR (25,809,944 for, 2 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,674,170 | 2 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,402,882 | 0 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 201,842 | 0 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.
95% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Proposal 5: Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan”): 59,389,193 for, 3,066,087 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 63% for, 3% against (66% of the company cast a for/against vote).
The 65 asset managers below cast 93% of the shares they voted on this item FOR (24,024,308 for, 1,768,615 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,802 | 8,371 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,663 | 3,219 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 1,600,223 | 0 | 0 | Against |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 201,842 | 0 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 0 | 85,615 | 0 | 0 | Against |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Lee N. Newcomer, M.D”): 61,576,936 for, 894,837 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 65% for, 1.0% against (66% of the company cast a for/against vote).
The 64 asset managers below cast 99.6% of the shares they voted on this item FOR (25,727,286 for, 79,551 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,809 | 8,364 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,758 | 3,124 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 134,262 | 67,580 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Paul M. Bisaro”): 61,842,900 for, 637,156 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 65% for, 0.7% against (66% of the company cast a for/against vote).
The 64 asset managers below cast 99.6% of the shares they voted on this item FOR (25,727,287 for, 79,550 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,810 | 8,363 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,758 | 3,124 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 134,262 | 67,580 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Rashmi Kumar”): 60,399,633 for, 2,071,375 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 64% for, 2% against (66% of the company cast a for/against vote).
The 64 asset managers below cast 99.0% of the shares they voted on this item FOR (25,556,187 for, 250,650 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,808 | 8,365 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,758 | 3,124 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 134,262 | 67,580 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 163,411 | 0 | 0 | Against |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026”): 76,302,595 for, 1,391,172 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 81% for, 1% against (82% of the company cast a for/against vote).
The 64 asset managers below cast 96% of the shares they voted on this item FOR (24,692,232 for, 1,114,604 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,670,068 | 4,105 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,402,787 | 95 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 1,110,404 | 0 | 0 | Against |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 201,842 | 0 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
95% Majority: yes · of votes cast
Myriad Genetics, Inc.’s own tally for this item (“Proposal 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement”): 59,356,710 for, 3,098,966 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 94,448,210 outstanding shares: 63% for, 3% against (66% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (107 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 107 | 0 | 0 | 0 | For |
| Verdad Advisers, LP | 0 | 0 | 0 | 0 | -- |
Ranked by the number of Myriad Genetics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 94,448,210 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 8.96% |
| 2 | Vanguard | 8.00% |
| 3 | GLENVIEW CAPITAL MANAGEMENT, LLC | 5.73% |
| 4 | DE Shaw | 4.55% |
| 5 | State Street | 4.48% |
| 6 | Charles Schwab | 3.82% |
| 7 | Federated Hermes | 3.58% |
| 8 | Fidelity | 3.51% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.46% |
| 10 | Aberdeen | 2.35% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock Portfolio Management LLC | 10.48% | 13G |
| BlackRock | 9.41% | 13F |
| Vanguard Group | 8.71% | 13F |
| Millennium Management | 7.06% | 13F |
| D.E. Shaw | 4.76% | 13F |
| State Street | 4.68% | 13F |
| Morgan Stanley | 3.82% | 13F |
| Goldman Sachs | 2.51% | 13F |
| Geode Capital | 2.46% | 13F |
| Charles Schwab | 1.91% | 13F |
Percentages above are of 94,448,210 shares outstanding, as reported by Myriad Genetics, Inc. on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Myriad Genetics, Inc.’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Myriad Genetics, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 229 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,762 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Myriad Genetics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.
Myriad Genetics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).